FDA warned Abraxis Bioscience about repeated contamination in media fills for sterile Abraxane at its Phoenix plant.
What happened
FDA inspected the Phoenix facility from March 28 to April 6, 2022. It found multiple media fill failures from April to October 2021 on the aseptic filling line for Abraxane; media fills simulate sterile filling and showed contaminated units. FDA said the investigations and corrective actions were inadequate, and the company released potentially affected batches after one successful November 2021 media fill.
What FDA found
The company failed to thoroughly investigate unexplained discrepancies or batch failures, including media fill failures.
21 CFR 211.192The company failed to effectively carry out corrective and preventive actions (CAPA) and bring its aseptic filling line back into control after repeated media fill failures.
21 CFR parts 210 and 211The media fill investigations did not adequately determine root causes or the full impact of serious non-sterility risks.
The company released batches potentially affected by the media fill failures after one successful November 2021 media fill.
The company's response was inadequate because contaminated media fills recurred and it lacked a comprehensive contamination risk assessment and holistic remediation.
The company did not adequately evaluate the suitability and robustness of disposable aseptic equipment and sampling systems, or disinfection of the restricted access barrier system (RABS) and cleanrooms.
What FDA wants
FDA asks Abraxis to provide a comprehensive contamination risk assessment, detailed remediation and CAPA plans, independent reviews of investigations and sterilization, a list of Abraxane complaints since 2019, and an updated patient-risk assessment for certain batches, and to respond in writing within 15 working days.
Who should pay attention
- makers of sterile injectables
- companies using similar disposable aseptic filling systems
- clinicians and distributors handling Abraxane
This is a summary. Read the original letter on fda.gov.